Spots Global Cancer Trial Database for b cell malignancies
Every month we try and update this database with for b cell malignancies cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients. | NCT06375161 | B Cell Malignan... | anti-CD19-CAR-T... | 18 Weeks - 70 Weeks | Shanghai Tongji Hospital, Tongji University School of Medicine | |
| CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | NCT00924326 | Primary Mediast... Diffuse, Large ... Diffuse Large B... Mantle Cell | Fludarabine Cyclophosphamid... Anti-cluster of... Aldesleukin Fludarabine Cyclophosphamid... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies | NCT01957579 | Blood Cancer Advanced B Cell... | MEDI-551 | 20 Years - 130 Years | AstraZeneca | |
| A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | NCT06205290 | Leukemia, Lymph... | Liso-cel Idelalisib Rituximab Bendamustine Fludarabine Cyclophosphamid... | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
| 4SCAR19U T Cells Targeting B Cell Malignancies | NCT05995015 | B Cell Malignan... | Universal CD19-... | 6 Months - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | NCT06205290 | Leukemia, Lymph... | Liso-cel Idelalisib Rituximab Bendamustine Fludarabine Cyclophosphamid... | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | NCT05618028 | Diffuse Large B... Chronic Lymphoc... B Cell Malignan... Non-Hodgkin's L... | ABBV-525 | 18 Years - | AbbVie | |
| A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation | NCT00672152 | Acute Myelogeno... Chronic Myeloge... Acute Lymphobla... Myelodysplastic... B Cell Malignan... | WT1 derived pep... | 18 Years - | Duke University | |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | NCT05618028 | Diffuse Large B... Chronic Lymphoc... B Cell Malignan... Non-Hodgkin's L... | ABBV-525 | 18 Years - | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
